Jan 09, 2024 / 05:45PM GMT
Richard Vosser - JPMorgan Chase & Co, Research Division - Senior Analyst
Welcome to the Novo Nordisk session at the 2024 JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan, and it's my great pleasure to welcome the CEO of Novo, Lars Fruergaard Jorgensen, to the conference for the first time.
So we're going to do this session slightly differently, and it's going to be more of a chat between us. But ahead of that, I'm going to hand over to Lars for a few introductory remarks. Lars, welcome to the conference.
Lars Fruergaard Jorgensen - Novo Nordisk A/S-President - CEO & Member of Management Board
Thank you, Richard, and thank you to JPMorgan for hosting all of us. Right now, it's a truly exciting moment in Novo Nordisk in '23. We celebrated our 100 year anniversary, and we did that by growing 30-plus percent. There's still a bit of numbers to be counted, so we are truly excited about the momentum we have obviously fueled by our GLP-1 business.
We have
Novo Nordisk A/S at JPMorgan Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers